Clinical Trial Update: Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating spironolactone to improve apnea and cardiovascular markers in obstructive sleep apnea has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obstructive Sleep Apnea

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: University of Michigan | Conditions: Obstructive Sleep Apnea | Phase 4 | Status: WITHDRAWN